U klikt door naar een site van derden.

GSK aanvaardt betreffende het gebruik van websites in beheer door derden, inclusief hun inhoud, geen enkele verantwoordelijkheid.

Verder

Ga terug

Product menu

NA

Which of your patients could benefit from EXDENSUR?

Within the approved indications, there are typical patient profiles. Which of these patients do you recognize from your daily practice?

Teaser Asthma

Patient profiles in severe, uncontrolled Type 2 asthmaa

Typical patient cases where EXDENSUR may make a difference.

View Patient Profiles
Teaser CRSwNP

Patient profiles in severe, uncontrolled CRSwNPb

A typical patient case where EXDENSUR may make a difference.

View Patient Profile

  • Footnotes

    a EXDENSUR (depemokimab) is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids(ICS) plus another asthma controller.1

    b EXDENSUR (depemokimab) is indicated as add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.1

  • References

    1. GlaxoSmithKline EXDENSUR (depemokimab). Summary of Product Characteristics (SmPC). 2026.

PM-BE-DEPE-WCNT-260014 - September 2026